Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US…

With a relatively high number of genetic disorders, the Arab population of the United Arab Emirates (UAE) is increasingly becoming the subject of new…

Rahja Daher, head of the Health Group for the Swiss Business Council (SBC) Dubai & Northern Emirates discusses the association’s formation,…

Paolo Carli, head of Middle East, Africa, Turkey, Russia and CIS (MEAR) for Merck has continually taken on greater responsibilities in the Middle…

Khaled Elrefae, Middle East and Africa Specialty Care Operations Head (GM) for Ipsen, highlights Ipsen’s impressive internationalization strategy…

The United Arab Emirates Genetic Diseases Association (UAEGDA) was established in 2006 and aims to increase awareness programs in order to prevent the…

Since we last met with Paolo Carli in 2013, he has been given greater responsibilities within Merck and is now Head of Middle East, Africa, Turkey,…

Ana Raposo, country director for Gulf Countries at Janssen discusses her role, the main similarities and differences between the various markets…

The UAE pharma market is projected to grow over 80 percent by 2027, in part due to a growing demand for the treatment of lifestyle diseases and…

The UAE ranks among the world's fastest for new drug approvals, ranking first for two cancer drugs and second for many others, such as blockbuster…

The UAE ranks as a world leader in rapid drug approvals with its fast-track registration system that accelerates the process and eliminates long…

Dubai's government has announced its ambition to go completely paper-free by the end of the year 2021. Its health authority has recently upgraded to a…